SHIP1-IN-1

SHIP1-IN-1 (compound 32) inhibits the human two‑domain SHIP1 protein construct with an IC₅₀ of 384 μM, the human five‑domain SHIP1 protein construct with an IC₅₀ of 177 μM, and the murine five‑domain SHIP1 protein construct with an IC₅₀ of 379 μM^[1].
SHIP1-IN-1 (1.0-10 μM) modulates the phosphoinositide association profile of the human five-domain SHIP1 protein, increasing relative binding to PI(3,4)P₂ at higher concentrations^[1].
SHIP1-IN-1 (60 min treatment at 37 °C; 3 min heating at 44.2 °C) engages full-length SHIP1 in HMC3 cells, reducing protein thermal stability with an AC₅₀ of 40.4 μM^[1].
SHIP1-IN-1 (15 min) modulates proximal SHIP1-dependent AKT signaling in IL-4-conditioned THP-1 cells, reducing the pAKT (S473)/tAKT ratio with an IC₅₀ of 4.0 μM and the pAKT (T308)/tAKT ratio with an IC₅₀ of 5.3 μM^[1].
SHIP1-IN-1 enhances pHrodo-myelin/membrane debris uptake in both BV2 murine microglia (EC₅₀ = 0.777 μM) and primary murine microglia (EC₅₀ = 0.484 μM), while reducing cell count and nuclear intensity with IC₅₀ values of 3.45 and 6.46 μM in BV2 cells, and 5.65 and 19.4 μM in primary microglia, respectively^[1].
SHIP1-IN-1 (50 nM-950 μM; 20 min pre-incubation with enzyme, 10 min reaction with substrate) inhibits purified SHIP1 Ptase-C2 domain activity with an IC₅₀ of 302 μM^[2].
SHIP1-IN-1 (Example 9) increases phagocytosis, reduces cell count, and alters nuclear intensity in primary mouse microglia in an in vitro high-content imaging assay^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.